BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 26.81 Million USD | -1.49% |
| 2022 | 27.21 Million USD | -23.24% |
| 2021 | 35.46 Million USD | 17.2% |
| 2020 | 30.25 Million USD | 36.25% |
| 2019 | 22.2 Million USD | 77.73% |
| 2018 | 12.49 Million USD | 71.71% |
| 2017 | 7.27 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.55 Million USD | 29.57% |
| 2024 Q2 | 9.39 Million USD | 43.29% |
| 2023 Q4 | 5.06 Million USD | -35.09% |
| 2023 Q1 | 6.2 Million USD | 11.65% |
| 2023 FY | 26.81 Million USD | -1.49% |
| 2023 Q3 | 7.79 Million USD | 28.36% |
| 2023 Q2 | 6.07 Million USD | -2.17% |
| 2022 Q3 | 6.54 Million USD | -10.58% |
| 2022 FY | 27.21 Million USD | -23.24% |
| 2022 Q4 | 5.56 Million USD | -15.1% |
| 2022 Q2 | 7.32 Million USD | -5.93% |
| 2022 Q1 | 7.78 Million USD | -20.43% |
| 2021 Q2 | 7.3 Million USD | -15.78% |
| 2021 Q3 | 9.83 Million USD | 34.66% |
| 2021 Q4 | 9.78 Million USD | -0.49% |
| 2021 FY | 35.46 Million USD | 17.2% |
| 2021 Q1 | 8.67 Million USD | -4.39% |
| 2020 Q4 | 9.06 Million USD | 2.7% |
| 2020 Q3 | 8.83 Million USD | 38.1% |
| 2020 FY | 30.25 Million USD | 36.25% |
| 2020 Q1 | 5.96 Million USD | -73.13% |
| 2020 Q2 | 6.39 Million USD | 7.17% |
| 2019 Q1 | 93.1 Thousand USD | 489.69% |
| 2019 Q4 | 22.2 Million USD | 3487.93% |
| 2019 Q3 | 618.93 Thousand USD | 109.83% |
| 2019 FY | 22.2 Million USD | 77.73% |
| 2019 Q2 | 294.97 Thousand USD | 216.82% |
| 2018 Q1 | 1000.00 USD | 0.0% |
| 2018 Q3 | 650.00 USD | 0.0% |
| 2018 Q4 | 15.78 Thousand USD | 2329.08% |
| 2018 FY | 12.49 Million USD | 71.71% |
| 2017 FY | 7.27 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 16.405% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -189.318% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -130.183% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 48.436% |
| Azitra, Inc. | 8.3 Million USD | -222.967% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -200.0% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -290.745% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 7.512% |
| CEL-SCI Corporation | 31.47 Million USD | 14.811% |
| iBio, Inc. | 16.85 Million USD | -59.049% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 18.763% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -32.858% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | -7.851% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -92.469% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -107.893% |
| NanoViricides, Inc. | 8.51 Million USD | -214.862% |
| Oragenics, Inc. | 5.45 Million USD | -391.824% |
| BiomX Inc. | 26.81 Million USD | 0.0% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 16.342% |
| Palatin Technologies, Inc. | 34.67 Million USD | 22.66% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 32.655% |